Show simple item record

dc.contributor.authorHutchings, Martin
dc.contributor.authorRadford, John A
dc.contributor.authorAnsell, S. M.
dc.contributor.authorIllés, Árpád
dc.contributor.authorSureda, Anna
dc.contributor.authorConnors, J. M.
dc.contributor.authorSýkorová, Alice
dc.contributor.authorShibayama, Hirohiko
dc.contributor.authorAbramson, Jeremy S
dc.contributor.authorChua, Neil
dc.contributor.authorFriedberg, Jonathan W
dc.contributor.authorKořen, Jan
dc.contributor.authorLaCasce, Ann Steward
dc.contributor.authorMolina, Lysiane
dc.contributor.authorEngley, Gerald
dc.contributor.authorFenton, K.
dc.contributor.authorJolin, Hina
dc.contributor.authorLiu, Rachael
dc.contributor.authorGautam, Ashish
dc.contributor.authorGallamini, Andrea
dc.date.accessioned2021-08-24T15:01:23Z
dc.date.available2021-08-24T15:01:23Z
dc.date.issued2021-04
dc.identifier.citationHutchings, M, Radford, J, Ansell, S.M, Illés, Á, Sureda, Anna, Connors, J.M, et al. Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced-stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high-risk patients from the ECHELON-1 study. Hematological Oncology. 2021 Apr;39(2):185-195.en_US
dc.identifier.issn0278-0232
dc.identifier.pmid33462822
dc.identifier.doi10.1002/hon.2838
dc.identifier.urihttp://hdl.handle.net/10541/624500
dc.description.abstractApproximately one-third of patients diagnosed with Hodgkin lymphoma presenting with Stage IV disease do not survive past 5 years. We present updated efficacy and safety analyses in high-risk patient subgroups, defined by Stage IV disease or International Prognostic Score (IPS) of 4-7, enrolled in the ECHELON-1 study that compared brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A + AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as first-line therapy after a median follow-up of 37.1 months. Among patients treated with A + AVD (n = 664) or ABVD (n = 670), 64% had Stage IV disease and 26% had an IPS of 4-7. Patients with Stage IV disease treated with A + AVD showed consistent improvements in PFS at 3 years as assessed by investigator (hazard ratio [HR], 0.723; 95% confidence interval [CI], 0.537-0.973; p = 0.032). Similar improvements were seen in the subgroup of patients with IPS of 4-7 (HR, 0.588; 95% CI, 0.386-0.894; p = 0.012). The most common adverse events (AEs) in A + AVD-treated versus ABVD-treated patients with Stage IV disease were peripheral neuropathy (67% vs. 40%) and neutropenia (71% vs. 55%); in patients with IPS of 4-7, the most common AEs were peripheral neuropathy (69% vs. 45%), neutropenia (66% vs. 55%), and febrile neutropenia (23% vs. 9%), respectively. Patients in high-risk subgroups did not experience greater AE incidence or severity than patients in the total population. This updated analysis of ECHELON-1 shows a favorable benefit-risk balance in high-risk patients.en_US
dc.language.isoenen_US
dc.relation.urlhttps://dx.doi.org/10.1002/hon.2838en_US
dc.titleBrentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced-stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high-risk patients from the ECHELON-1 studyen_US
dc.typeArticleen_US
dc.identifier.eissn1099-1069
dc.contributor.departmentDepartment of Haematology and Phase 1 Unit, Rigshospitalet, Copenhagen, Denmarken_US
dc.identifier.journalHematological Oncologyen_US
refterms.dateFOA2021-08-24T15:01:24Z


This item appears in the following Collection(s)

Show simple item record